Trial reportCancer discovery2017
Secondary Somatic Mutations Restoring
Open access · greenAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 258 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
258citing papers in PubMed, 3 pooled it
17.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
258 citing papers in PubMed, 3 syntheses or guidelines pooled it, 403 citations in OpenAlex.
- Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.Cell death & disease · 2022Pooled it
- PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations.JCO precision oncology · 2021Pooled it
- Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Pooled it
- Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.British journal of cancer · 2026Trial
- Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion.Proceedings of the National Academy of Sciences of the United States of America · 2026Trial
- A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.Gynecologic oncology · 2024Trial
- Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.JCO precision oncology · 2023Trial
- Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.Gynecologic oncology · 2022Trial
- A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.Journal of gynecologic oncology · 2022Trial
- Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).Nature communications · 2021Trial
- Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation.Signal transduction and targeted therapy · 2026Review
- Mechanisms and disease relevance of DNA break repair pathway choice.Nature reviews. Molecular cell biology · 2026Review
- RAD51C breast cancer-identified variants with attenuated homologous recombination function exhibit sensitivity to combined PARP1 and ATR inhibition.NAR cancer · 2026Article
- RAD51 in Breast Cancer: From Vulnerability to Resistance.World journal of oncology · 2026Review
- PARP Inhibitor Sensitivity in Tumors Harboring Non-BRCA Homologous Recombination Gene Alterations: Current Evidence Across Ovarian, Breast, Prostate, and Pancreatic Cancers.International journal of molecular sciences · 2026Review
- The role of circulating tumor DNA in ovarian cancer.Discover oncology · 2026Review
- RAD51-targeting small molecule degrader sensitizesActa pharmaceutica Sinica. B · 2026Article
- Review
- Hierarchies of resistance to DNA damage response inhibitors: from pathway restoration to replication stress tolerance.Experimental hematology & oncology · 2026Review
- Article
198 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
36 authors at 1 institution in 1 country.
Olga KondrashovaWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Minh NguyenClovis Oncology, Inc., Boulder, Colorado.
Kristy Shield-ArtinWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Anna V TinkerBritish Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Nelson N H TengStanford University, Palo Alto, California.
Maria I HarrellUniversity of Washington, Seattle, Washington.
Michael J KuiperMelbourne Bioinformatics, The University of Melbourne, Melbourne, Victoria, Australia.
Gwo-Yaw HoWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Holly BarkerWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Maria JasinDevelopmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Rohit PrakashDevelopmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Elizabeth M KassDevelopmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Meghan R SullivanDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Gregory J BrunetteDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Kara A BernsteinDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Robert L ColemanThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Anne FloquetInstitut Bergonié, Bordeaux, France.
Michael FriedlanderUniversity of New South Wales and Prince of Wales Hospital, Sydney, New South Wales, Australia.
Ganessan KichenadasseFlinders University, Adelaide, South Australia, Australia.
David M O'MalleyThe Ohio State University, James Cancer Center, Columbus, Ohio.
Amit OzaPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
James SunFoundation Medicine, Inc., Cambridge, Massachusetts.
Liliane RobillardClovis Oncology, Inc., Boulder, Colorado.
Lara MaloneyClovis Oncology, Inc., Boulder, Colorado.
David Bowtell
Heidi GiordanoClovis Oncology, Inc., Boulder, Colorado.
Matthew J WakefieldWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Scott H KaufmannMayo Clinic Cancer Center, Rochester, Minnesota.
Andrew D SimmonsClovis Oncology, Inc., Boulder, Colorado.
Thomas C HardingClovis Oncology, Inc., Boulder, Colorado.
Mitch RaponiClovis Oncology, Inc., Boulder, Colorado.
Iain A McNeishInstitute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
Elizabeth M SwisherUniversity of Washington, Seattle, Washington.
Kevin K LinClovis Oncology, Inc., Boulder, Colorado.
Clare L ScottWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia. scottc@wehi.edu.au.
AOCS Study Group
BC Cancer Agency · CA
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0MVaccinating against IGFBP-2 to prevent ovarian cancer relapseP50CA083636 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DRESCHER, CHARLES, URBAN, NICOLE DENISE · 1999 to 2015
$35.1MHOMOLOGY-DIRECTED DNA REPAIR PROTEINS BRCA2 AND RAD51 PARALOGS IN TUMOR-RELEVANT TISSUESR01CA185660 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JASIN, MARIA · 2014 to 2020
$2.7MReplication fork dynamics and repair by Rad51 paralogues after DNA alkylationR01ES024872 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BERNSTEIN, KARA A · 2015 to 2019
$2.4MMechanisms of PARP Inhibitor Resistance in Ovarian CancerR01CA190423 · NCI · MAYO CLINIC ROCHESTER · PI KAUFMANN, SCOTT H · 2015 to 2019
$1.9MDeciphering the epistatic relationships of RAD51 Paralogs in mammary epitheliumF32GM110978 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI PRAKASH, ROHIT · 2014 to 2015
$117kCancer Research UK 15973Medical Research Council G0601891NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA083636NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA185660NCI NIH HHS R01 CA190423NIEHS NIH HHS R01 ES024872NIGMS NIH HHS F32 GM110978
Abstract
High-grade epithelial ovarian carcinomas containing mutated
Indexed as
AnimalsCell Line, TumorCHO CellsCricetulusDNA-Binding ProteinsDrug Resistance, NeoplasmFemaleHEK293 CellsHumansIndolesMutationOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsDNA-Binding ProteinsIndolesPoly(ADP-ribose) Polymerase InhibitorsRAD51C protein, humanRAD51D protein, humanrucaparib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.